Earnings Call · Q4 FY2024·2025-03-12

Q4 24EPS -27.27%·Rev n/aQ3 24EPS -100.00%*·Rev n/aQ2 24EPS -15.00%·Rev n/aQ1 24EPS +80.00%·Rev n/a⚠ consensus missing

Anika Therapeutics, Inc. ANIK

Matt Hall — Director of Corporate Development and Investor Relations

Cheryl Blanchard — Chief Executive Officer

Steve Griffin — Chief Financial Officer

+1.9%1d on move date+1.4% vs SPY3d−5.2%5d−5.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ANIK calls or request research access.

More ANIK calls Browse calls Request research access